Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis.

Authors

• C S Constantinescu
• B Hilliard
• E Ventura
• A Rostami

Publication/Presentation Date

1-1-1997

Abstract

Melatonin has immune-enhancing effects and can exacerbate autoimmunity. Pinealectomy or light exposure, which suppress melatonin, inhibit T cell autoimmunity. To investigate the involvement of melatonin in experimental autoimmune encephalomyelitis (EAE), a T-cell-mediated autoimmune demyelinating disease, we tested the effect of luzindole, a melatonin receptor antagonist, on EAE. Luzindole-treated mice did not develop EAE after immunization with spinal cord homogenate, whereas control mice developed EAE. This study suggests that pharmacological inhibition of the immunoenhancing effects of melatonin may prevent autoimmune demyelination.

Volume

65

Issue

4

First Page

190

Last Page

194

ISSN

1015-2008

Published In/Presented At

Constantinescu, C. S., Hilliard, B., Ventura, E., & Rostami, A. (1997). Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. Pathobiology : journal of immunopathology, molecular and cellular biology, 65(4), 190–194. https://doi.org/10.1159/000164122

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

9396042

Department(s)

Administration and Leadership

Document Type

Article